Topical cytotoxics (Formulary: Malignant disease)

Important: Formulation and dosage details

Formulation:

Gel 160 micrograms/g (Ledaga®) (Restricted: Hospital use only)

Dosage:

Indication as per SMC 2318: for the topical treatment of mycosis fungoides-type cutaneous T cell lymphoma (MF-type CTCL) in adult patients. 

Place in therapy: To be used when there is insufficient response to topical steroid and phototherapy.

Notes:

Storage: 

• Unopened tube: Store and transport frozen (-15°C to -25°C) or refrigerated (+2°C to +8°C).
• After defrosting: Store and transport refrigerated (+2°C to +8°C).

Disposal: A purple-lidded waste container must be used.

• Ledaga is a cytotoxic medicinal product.
• Caregivers must wear nitrile gloves when handling Ledaga®.  Patients and caregivers must wash hands after handling Ledaga®.
• Ledaga® is an alcohol-based product and is flammable.  The recommended application instructions should be followed.
• Unused refrigerated Ledaga® should be discarded after 60 days, together with the plastic bag.  Any unused medicinal product or waste material, including the plastic bag and the nitrile gloves used for application, must be disposed of in accordance with local requirements.

For full details, see: Ledaga 160 micrograms/g gel - Summary of Product Characteristics (SmPC) - (emc) | 10384

Important: Formulation and dosage details

Formulation:

Formulation:

Cream 5% (Efudix)